Endocrinology

DKA Knowledge Challenge!

Diabetic ketoacidosis isn’t just an emergency room concern. It can start with subtle signs you might see first in your patients. This quick quiz zeroes in on the key red flags, risk factors, and management essentials of DKA that every PCP should know. Test your knowledge and sharpen your clinical instincts - it could make all the difference.

Click here to participate in survey

Latest News

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase
Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

June 24th 2025

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

FDA, EMA Grant Lu AG13909 Orphan Drug Status for Treatment of Congenital Adrenal Hyperplasia / image credit ©pivovit/stock.adobe.com
FDA, EMA Grant Lu AG13909 Orphan Drug Status for Treatment of Congenital Adrenal Hyperplasia

June 24th 2025

 Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial / image credit American Diabetes Association
Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial

June 24th 2025

Orforglipron, Investigational Oral GLP-1, Cut HbA1c and Body Weight in People with T2D
Orforglipron, Investigational Oral GLP-1, Cut HbA1c and Body Weight in People with T2D

June 23rd 2025

Primary Care-Led Weight Management Intervention Prevents Weight Gain and Enhances Revenue: New Research
Primary Care-Led Weight Management Intervention Prevents Weight Gain and Enhances Revenue: New Research

June 23rd 2025

Video Interviews
Podcasts
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.